Morse Asset Management Inc Has $1.32 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Morse Asset Management Inc lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 61.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,855 shares of the biopharmaceutical company's stock after selling 2,952 shares during the period. Morse Asset Management Inc's holdings in Regeneron Pharmaceuticals were worth $1,321,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of REGN. Czech National Bank lifted its holdings in Regeneron Pharmaceuticals by 5.6% in the fourth quarter. Czech National Bank now owns 22,826 shares of the biopharmaceutical company's stock valued at $16,260,000 after acquiring an additional 1,209 shares during the last quarter. Wedmont Private Capital lifted its stake in Regeneron Pharmaceuticals by 14.1% during the fourth quarter. Wedmont Private Capital now owns 1,707 shares of the biopharmaceutical company's stock worth $1,190,000 after purchasing an additional 211 shares in the last quarter. Moody National Bank Trust Division acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth $1,067,000. Sivia Capital Partners LLC raised its stake in shares of Regeneron Pharmaceuticals by 23.8% in the fourth quarter. Sivia Capital Partners LLC now owns 343 shares of the biopharmaceutical company's stock valued at $244,000 after acquiring an additional 66 shares in the last quarter. Finally, MRA Advisory Group raised its stake in shares of Regeneron Pharmaceuticals by 36.3% in the fourth quarter. MRA Advisory Group now owns 590 shares of the biopharmaceutical company's stock valued at $420,000 after acquiring an additional 157 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on REGN shares. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. BMO Capital Markets dropped their price objective on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Bernstein Bank dropped their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 22nd. Finally, Guggenheim decreased their target price on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $890.60.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $9.33 on Friday, reaching $594.32. The company's stock had a trading volume of 935,531 shares, compared to its average volume of 788,324. The firm has a market cap of $64.17 billion, a PE ratio of 15.53, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The business has a 50-day moving average price of $602.44 and a 200 day moving average price of $686.93. Regeneron Pharmaceuticals, Inc. has a 52 week low of $520.50 and a 52 week high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue was down 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $9.55 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.59%. Regeneron Pharmaceuticals's dividend payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.